Topic
biotech
60 stories related to this topic, newest first.
americanbanker.comscience5 hrs agoUpdated
Bipartisan Lawmakers Reintroduce Bill Ordering FTC and Treasury Review of Foreign Drug Manufacturing
Three lawmakers on July 15, 2026, reintroduced legislation directing the FTC and Treasury to examine foreign dependence in prescription drug manufacturing. The measure also targets risks from moving domestic facilities overseas.
Statscience10 hrs ago
Johnson & Johnson Reports Second-Quarter Earnings Alongside Biotech Study Results
Johnson & Johnson released its second-quarter results on July 15, 2026. Separate midstage and Phase 3 studies showed progress for an oral minoxidil formulation and a targeted chemotherapy drug.
Statscience1 day ago
FTC Settles Lawsuit With CVS Caremark Over Insulin Pricing Allegations
The Federal Trade Commission reached a settlement with CVS Caremark on July 14, 2026, requiring changes to its pharmacy benefit practices. The agreement addresses claims that the company inflated insulin prices through a rebate system. Stat reported the deal is projected to deliv…
abcnews.go.comworld1 day ago
Experimental Drug Diranersen Lowers Tau but Shows Mixed Results on Cognitive Decline in Early Alzheimer’s Study
Researchers presented results Tuesday from a 400-person trial of diranersen at the Alzheimer’s Association International Conference in London. The lowest dose given every six months produced the clearest signal of reduced decline on multiple cognitive measures.
abcnews.go.comscience1 day ago
Biogen’s diranersen slowed cognitive decline in Phase 2 Alzheimer’s trial; experts await Phase 3 data
Biogen said its tau-targeting Alzheimer’s candidate diranersen reduced cognitive decline at rates similar to approved drugs in a mid-stage study. The company plans to advance the treatment into Phase 3 testing.
prnewswire.comworld1 day ago
AstraZeneca pays Dizal $600 million upfront for global rights to lung-cancer drug, with up to $900 million more in milestones
AstraZeneca will pay Dizal Pharmaceutical $600 million upfront for global rights to a lung cancer treatment. Dizal could receive another $900 million in milestone payments.
vox.comscience5 days ago
ARPA-H Commits $160 Million to Custom Gene Editing for Rare Diseases
@statnews reported that ARPA-H will fund seven teams developing personalized gene editing treatments. The biggest nursing strike in Massachusetts history ended amid clashes at Brigham and Women’s Hospital, while the FDA set a November deadline on banning electrical stimulation de…
wwd.comscience6 days ago
Prime Medicine Wins Arbitration Against Beam Therapeutics Over Gene-Editing Agreement
An arbitrator ruled that Prime Medicine's work on an AATD drug did not violate a 2019 agreement with Beam Therapeutics. The decision clears the way for Prime to begin a clinical trial this quarter.
wwd.comscience6 days agoUpdated
ARPA-H to Fund Up to $160 Million for Experimental Gene-Editing Treatments for Rare Diseases
The U.S. health research agency will fund seven teams to develop personalized gene editing therapies for rare diseases. The effort sets a three-year deadline for starting clinical trials.
marketscreener.comscience6 days ago
AstraZeneca Shares Fall 9% After Wainua Heart Drug Trial Misses Primary Endpoint
London-listed shares of the British drugmaker dropped as much as 9 percent Thursday after late-stage results showed Wainua failed to reduce deaths and heart events in patients with transthyretin-mediated amyloid cardiomyopathy. The outcome also pushed shares of partner Ionis Phar…
marketscreener.comscience6 days ago
AstraZeneca shares fall after Wainua trial misses death reduction goal
AstraZeneca shares declined after its drug Wainua did not lower death rates in a heart condition study. The company reported the trial results and investors reacted to the outcome.
.png)
Wiredtechnology8 days ago
Mass Balance Launches Grapefruit-Sized Apparatus on SpaceX Mission
The British startup sent a self-running chemical experiment into orbit Tuesday aboard a SpaceX transporter. The two-month test collects microgravity data on cells and reactions to support AI models for disease research.
science9 days ago
Vertex to Buy Crinetics for $10 Billion, Largest Deal in Its History
Vertex Pharmaceuticals announced it will buy Crinetics Pharmaceuticals for $10 billion, or $85 per share. The transaction marks Vertex's largest acquisition and adds a commercial drug for acromegaly plus a late-stage candidate for congenital adrenal hyperplasia.
news.sky.comscience9 days ago
Wegovy weight loss pill now available privately in UK
The once-daily semaglutide tablet can be purchased from pharmacies for eligible adults. It is not yet available on the NHS and requires a consultation.
cnbc.comworld9 days ago
Wegovy weight-loss pill now sold privately in UK pharmacies
A once-daily semaglutide tablet is available for private purchase from UK pharmacies. The pill carries the same eligibility rules and dosing schedule as the injectable version and is not yet offered by the NHS.
Forbestechnology12 days ago
Trump Administration Proposes Rules to Apply Medicare Price Negotiations to Some Reformulated Drugs
The Centers for Medicare and Medicaid Services last month proposed rules to group reformulated drugs with their originals for negotiation eligibility. The changes target biologics switched from intravenous to subcutaneous forms and would take effect with the 2029 price applicabil…
finance.yahoo.comscience13 days ago
Abivax Shares Rise After Company Announces Financing Move
Abivax shares continued to climb following the biotech company's announcement of steps to strengthen its balance sheet. The move comes as the firm seeks additional capital resources.
FI
science13 days ago
Roche Lung-Cancer Drug Candidate Outperforms Standard Treatments in Late-Stage Trial
A Roche experimental lung-cancer therapy showed better results than current standard treatments in a late-stage clinical trial. The company reported the outcome through a Wall Street Journal account.
LI
forbes.comscience14 days ago
Eli Lilly Leads $100 Million Round in AI Drug Developer Absci
Eli Lilly participated in a $100 million stock offering for Absci, an AI-focused drug company. The investment targets development of an injectable antibody for hair loss and endometriosis.
science14 days ago
Ipsen Agrees to Acquire Kartos Therapeutics
French drugmaker Ipsen will buy U.S.-based Kartos Therapeutics, which is developing a treatment for a rare blood cancer. The deal is Ipsen’s second acquisition this week.
biopharmadive.comscience15 days ago
Beeline Medicines Raises $126.3 Million in Series A Extension
Bain Capital Life Sciences-backed startup Beeline Medicines secured additional funding. Separately, the acting director of the FDA office reviewing cell and gene therapies announced his departure. Both developments were reported June 30, 2026.
theverge.comai15 days ago
Anthropic Releases Claude Science Tool for Lab and Drug Research
Anthropic announced Claude Science on Tuesday to optimize its large language model for scientific laboratories and pharmaceutical operations. The company reported $42 billion in annualized sales and a $965 billion valuation last month.
biopharmadive.comscience15 days ago
Nearly 1 Million Bottles of Heart Failure Drug Recalled
A nationwide recall covers 934,577 bottles of Corlanor after the manufacturer reported possible foreign substance contamination. The FDA classified the action as Class II, indicating temporary or reversible health risks.
winnipegfreepress.comscience15 days ago
Health Canada Approves First Generic Version of Wegovy for Weight Loss
Health Canada approved Svemia, a generic semaglutide injection filed by Apotex, for chronic weight management in people age 12 and older. The once-weekly treatment must be used with diet and exercise.
theconservativetreehouse.comscience15 days ago
Trump Administration Sets $245 Monthly Price for GLP-1 Drugs in Medicare and Medicaid with $50 Copay Requirement
The November agreement with Eli Lilly and Novo Nordisk covered obesity indications previously excluded from Medicare. Coverage required private Medicare insurers to offer the drugs at a $50 copay.
Statscience15 days ago
Abivax Releases Additional Maintenance Trial Data on Obefazimod
Abivax released additional Phase 3 maintenance trial data for obefazimod late Monday. The update showed cancer rates aligned with background expectations after earlier concerns. U.S.-listed shares gained about 25% overnight.
science16 days ago
Talawar Therapeutics to list publicly through reverse merger with JATT II Acquisition Corp and $225 million financing
@statnews reported that Talawar Therapeutics plans to go public through a reverse merger with JATT II Acquisition Corp. The transaction includes a $225 million PIPE financing. The company said the funds will support its lead program through mid-stage clinical testing.
macaubusiness.comscience16 days ago
Moderna Co-Founder Kenneth Chien Discusses mRNA Technology in June 29 Interview
STAT published an interview with Moderna co-founder Kenneth Chien on June 29, 2026. Chien addressed the future of mRNA technology and the company during the discussion.
ww2.kqed.orgscience17 days ago
Democratic lawmakers seek details on patient given early access to Eli Lilly obesity drug
Two Democratic members of Congress are asking the Trump administration for more information about a 79-year-old patient approved in April for compassionate-use access to an experimental obesity treatment. The lawmakers want to know whether the patient is a high-profile individual…
forbes.comscience17 days ago
Medicare Bridge Program Begins Obesity Drug Coverage for Part D Enrollees at $50 Monthly Copay
Eligible beneficiaries gained access to the treatments on July 1, 2025. A survey showed most seniors remained unaware of the change despite the program's extension through 2027.
Yonhapworld17 days ago
Samsung Biologics Union Votes to Leave Company-Wide Labor Group After Strikes
Unionized workers at Samsung Biologics approved a move to leave the Samsung Group United Union in a vote that ended Sunday. The decision follows months of labor actions over pay and conditions. Negotiations with management are set for this week.
indianexpress.comscience18 days ago
Pfizer and Valneva Plan Lyme Vaccine Filing Despite Missed Trial Goal
Pfizer and Valneva announced this spring plans to seek regulatory approval for a Lyme disease vaccine. Interviews with hunters show mixed interest depending on safety data and personal risk.
etftrends.comscience19 days ago
Base Editing in Human Embryos Avoids Chromosome Damage but Creates Mosaics
@statnews reported on June 26, 2026, that scientists used base editing in early human embryos to examine genes active in initial development stages. The approach avoided prior chromosome damage but produced mosaic embryos.
science19 days ago
Senate Health Committee Chair Introduces Bill to Restrict 340B Drug Discount Program
The legislation would let drugmakers issue retroactive rebates and impose new rules on hospitals and contract pharmacies. Separately, the Trump administration is considering Jeff Vacirca to lead the FDA.
Fox Newsscience19 days ago
Trump Administration Opens Section 301 Probe Into German Drug Pricing
The investigation follows Germany's proposal to pay less for U.S.-developed medicines. It will run through the fall with a public hearing set for Sept. 22. The move echoes an earlier tariff threat that led the United Kingdom to raise payments.
thenextweb.comworld19 days ago
European Commission Opens Antitrust Probe Into Sanofi Flu Vaccine Marketing; Company Says It Complied With Rules
The European Commission opened an antitrust investigation on Friday into whether Sanofi breached EU competition rules in a flu vaccine marketing campaign. The probe focuses on efforts to promote Efluelda while disparaging a rival product in France and Germany.
benzinga.comscience19 days agoUpdated
Senator Introduces Bill to Restrict 340B Drug Discount Program
Sen. Bill Cassidy introduced legislation on June 26, 2026, that would overhaul the federal 340B program by allowing retroactive rebates instead of upfront discounts. The measure would also require hospitals to pass savings to patients and impose limits on contract pharmacies.
FI
Statscience20 days ago
Eli Lilly grants one patient access to obesity drug candidate via FDA program
Eli Lilly and the Food and Drug Administration approved compassionate-use access to retatrutide for a single individual. The decision was discussed on a weekly biotech podcast alongside topics of drug acquisitions and hair-loss treatments.
benzinga.comscience20 days agoUpdated
Democratic lawmakers seek details on special access to experimental obesity drug
Two members of Congress are asking the White House for information on a 79-year-old patient granted early access to an experimental obesity treatment. The request follows reporting that the drug was provided through the FDA's compassionate use program.
axios.comscience20 days ago
U.S. Health Care Spending Reached $5.7 Trillion in 2025, or Nearly $16,500 per Person
@statnews reported that total spending rose 7.3 percent from 2024, with per-person costs near $16,500. Prescription drug outlays increased more than 11 percent amid higher utilization of services.
The Independentworld20 days ago
Novo Nordisk Seeks Wider Insurance Coverage for Weight-Loss Drugs
The company is pressing U.S. insurers to cover more of the cost of its GLP-1 medications. Direct consumer purchases now make up 30 percent of injectable sales and 90 percent of the new Wegovy pill.
thehindu.comscience21 days ago
Ollin Biosciences raises $330 million in Series B funding
Ollin Biosciences secured $330 million in a Series B round co-led by TCGX and ARCH Venture Partners. The capital supports upcoming Phase 3 testing of a treatment for diabetic macular edema and wet age-related macular degeneration.
vintagevalueinvesting.comscience22 days ago
Eli Lilly and Bayer Say German Policies Reduce Pharmaceutical Investment
Eli Lilly and Bayer stated that Germany's current approach to spending on innovative medicines could affect the country's appeal for future pharmaceutical projects. The companies linked their comments to existing reimbursement and pricing rules.
FI
benzinga.comscience22 days ago
Eli Lilly Provided Experimental Obesity Drug to One Patient via FDA Compassionate-Use Program
STAT reported that Eli Lilly supplied its experimental obesity drug retatrutide to a single 79-year-old man via the FDA’s compassionate-use pathway in April. The access drew attention from top health officials. Three sources requested anonymity citing fear of reprisals.
Statscience22 days ago
New gene-editing startup raises $230 million via reverse merger with troubled cancer-research firm
Serapha Bio launched June 23, 2026, after raising $230 million and completing a reverse merger. The startup will develop a one-time gene-editing therapy for Alpha-1 Antitrypsin Deficiency.
benzinga.comscience22 days ago
Eli Lilly Supplied Experimental Obesity Drug to One Patient via FDA Compassionate-Use Program
Stat reported that Eli Lilly supplied its experimental drug retatrutide to a single patient through the FDA’s compassionate-use pathway in April. The request involved a 79-year-old man and drew attention from senior health officials. Retatrutide has produced substantial weight lo…
fda.govscience23 days ago
FDA to Reconsider Gene Therapy for Rare Childhood Brain Disorder
The U.S. Food and Drug Administration will review an experimental gene therapy rejected four months earlier. The United States also opened a trade investigation into German plans to cut pharmaceutical spending by $23 billion.
New York Postscience23 days ago
Definium Shares Rise 55% After LSD-Based Drug Meets Main Goal in Depression Trial
Definium Therapeutics reported that a single dose of its experimental drug DT120 reduced major depression symptoms in a late-stage trial. Shares jumped 55% to a more than four-year high.
Statscience23 days agoUpdated
AbbVie to Acquire Apogee Therapeutics for $10.9 Billion
AbbVie will pay $10.9 billion in cash to buy Apogee Therapeutics, a Waltham-based developer of immunology drugs. The deal values Apogee shares at $135.11 each, a roughly 50 percent premium to the prior close.
cnbc.comscience23 days ago
FDA to Reconsider Gene Therapy for Rare Childhood Brain Disorder After Earlier Rejection
The U.S. Food and Drug Administration will review an experimental gene therapy for a deadly childhood brain disorder rejected four months earlier. The move follows leadership changes at the agency. A separate trade probe targets German pharmaceutical spending plans.
science23 days ago
AbbVie to Acquire Apogee Therapeutics for $10.9 Billion in Cash
@statnews reported that AbbVie will buy Apogee Therapeutics, an immunology drug developer, for $10.9 billion. The deal values Apogee shares at $135.11, a 50 percent premium to the prior close. Apogee's lead candidate targets IL-13 for atopic dermatitis and asthma.
newatlas.comscience23 days agoUpdated
Definium LSD therapy reduced depression scores in Phase 3 trial
Definium Therapeutics reported that its LSD-based drug DT120 produced larger reductions in depression scores than placebo in a late-stage study. The company said the results move the therapy closer to potential regulatory review.
etftrends.comscience23 days ago
Pharma and Large Biotech Firms Complete 32 Deals Worth $123 Billion in First Half of 2026
Pharmaceutical and large biotech firms spent about $123 billion on 32 deals of $1 billion or more in the six months through June 22, 2026. The total exceeds the $112 billion spent on 26 similar deals in all of 2025.
rte.iescience24 days ago
Arizona Newborn Diagnosed With Congenital Syphilis After Pfizer Did Not Ship Requested Bicillin L-A by April 7
A pregnant woman in Gila County received a syphilis diagnosis in late March 2026. The requested emergency dose of Bicillin L-A did not arrive before delivery, and the newborn tested positive for congenital syphilis.
upi.comscience24 days ago
U.S. Opens Drug Price Investigation Targeting Germany
The U.S. government announced an investigation into German drug pricing on June 19. Officials say the probe will examine whether underpayment for U.S. medicines is unreasonable or discriminatory.
manilatimes.netscience25 days ago
HHS Requests Testosterone Therapy Label Updates to Reflect New Safety Data
The Department of Health and Human Services asked for changes to testosterone replacement therapy labels on Thursday, including removal of a 2015 statement on age-related low testosterone.
forbes.comscience25 days ago
Meta-analysis finds tirzepatide produced largest weight loss among three GLP-1 drugs
A University of Georgia review of 14,000 non-diabetic patients showed tirzepatide led to more than 20 percent body-weight reduction, compared with roughly 15 percent for semaglutide and 8 percent for liraglutide.
Statscience26 days ago
Tennessee Pharmacies Sell High-Dose Ivermectin Without Prescriptions Under 2022 Law
Dozens of Tennessee pharmacies dispense concentrated ivermectin tablets under collaborative agreements that bypass individual prescriptions. State tracking of sales remains limited three years after the law took effect.
France 24science26 days ago
U.S. Opens Trade Investigation Into German Drug Pricing
The United States Trade Representative launched a probe on Thursday into whether Germany underpays for innovative medicines. The move follows months of talks and could lead to tariffs.
marketwatch.combusiness28 days ago
Cyber Group Says It Stole Data From Novo Nordisk, FDA Clears Path for Huntington's Treatment
A cyber extortion group reported stealing more than a terabyte of data from Novo Nordisk after an unsuccessful $25 million demand. The FDA reversed an earlier stance and accepted data supporting a marketing application for a Huntington's disease treatment.